STOK
Stoke Therapeutics Inc
24.70$
+3.3%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Cash Flow
Stoke Therapeutics Inc (STOK) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -57 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.0 | -2.4 | -3.0 | -3.5 | -6.5 | -6.3 | -8.0 | -10 | -11 | -9.6 | -11 | -11 | -20 | -16 | -15 | -16 | 32 | -20 | -22 | -22 | -21 | -22 | -17 | -21 | -25 | -17 | -22 | -23 | 132 | -25 | -30 | -30 | -61 | -57 | -178 | |
| 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.2 | 0.2 | 0.3 | 0.4 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 | 1.0 | 0.4 | 0.4 | 0.5 | 2.3 | |
| 0.0 | 0.1 | 0.0 | 0.1 | 0.2 | 0.3 | 0.7 | 0.7 | 0.8 | 1.6 | 1.8 | 1.6 | 2.7 | 4.5 | 4.6 | 4.7 | 5.0 | 6.2 | 5.9 | 5.8 | 5.9 | 6.8 | 6.7 | 6.1 | 5.5 | 7.4 | 7.6 | 7.1 | 6.8 | 7.6 | 8.0 | 9.8 | 8.8 | 11 | 37 | |
| 0.0 | 0.1 | 0.0 | – | 0.2 | 0.3 | 0.7 | 0.7 | 1.0 | 1.9 | 2.0 | 1.8 | 2.7 | 4.8 | 4.6 | 4.7 | 5.0 | 6.2 | 6.4 | 5.8 | 5.9 | 7.2 | 7.0 | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.1 | 0.5 | 0.2 | 0.6 | -1.1 | 1.1 | -0.3 | -0.9 | -0.9 | 1.2 | 0.5 | 1.5 | -6.6 | 1.1 | 2.7 | 2.8 | 51 | -2.1 | -2.7 | -3.5 | -5.9 | 1.1 | -0.4 | -0.9 | -4.7 | 0.0 | 0.6 | -20 | 12 | -11 | -1.1 | 17 | -20 | -8.6 | -13 | |
| 0.0 | 0.3 | 0.5 | 0.1 | 0.1 | 0.4 | 0.6 | 0.6 | 0.6 | 0.1 | 0.3 | 0.1 | 0.2 | 0.5 | 0.3 | 0.2 | 0.8 | 0.7 | 2.0 | 0.4 | 0.2 | 0.8 | 0.4 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | 0.2 | 0.2 | 0.1 | 0.2 | 0.4 | 2.0 | 2.7 | |
| 0.0 | -0.3 | -0.5 | -0.1 | -0.1 | -0.4 | -0.6 | -0.6 | -0.6 | -0.1 | -0.3 | -0.1 | -0.2 | -83 | -5.3 | 12 | -136 | 0.1 | 67 | 22 | 53 | 23 | 15 | 15 | 10.0 | -88 | -30 | 0.8 | 14 | -148 | 9.1 | -61 | 51 | 9.0 | 7.7 | |
| 0.0 | – | – | – | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | – | – | 116 | 0.1 | 152 | 152 | 152 | 0.2 | – | – | – | 0.5 | 0.2 | 0.4 | 0.2 | 0.3 | 0.3 | 0.4 | 0.0 | 0.3 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 12 | 0.1 | 13 | 90 | -0.1 | 151 | -1.0 | 0.2 | 0.2 | 0.4 | 0.7 | 107 | 0.5 | 0.2 | 0.4 | 0.2 | 43 | 3.4 | 0.4 | 0.0 | 45 | 0.0 | 0.6 | 7.3 | 1.7 | 121 | 8.2 | 0.6 | 1.4 | 0.6 | 3.1 | 92 | 84 | 1.9 | 182 | |
| 10 | -2.7 | 9.8 | 86 | -6.7 | 144 | -9.6 | -11 | -11 | -9.4 | -10 | 96 | -20 | -98 | -20 | -4.3 | -61 | -16 | 46 | 0.2 | 77 | 1.7 | -2.1 | 1.5 | -13 | 15 | -43 | -22 | 147 | -173 | -18 | 0.8 | 74 | -46 | 11 | |
| -2.0 | -2.7 | -3.6 | -3.6 | -6.6 | -6.7 | -8.6 | -11 | -11 | -9.7 | -11 | -11 | -20 | -16 | -15 | -16 | 32 | -21 | -24 | -23 | -22 | -23 | -18 | -21 | -25 | -18 | -22 | -23 | 132 | -26 | -30 | -31 | -61 | -59 | -181 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.